Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Benjamin Bitler to BRCA2 Protein

This is a "connection" page, showing publications Benjamin Bitler has written about BRCA2 Protein.

 
Connection Strength
 
 
 
0.928
 
  1. Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. Mol Cancer Ther. 2020 02; 19(2):602-613.
    View in: PubMed
    Score: 0.582
  2. Sanders BE, Ku L, Walker P, Bitler BG. Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer. Technol Cancer Res Treat. 2021 Jan-Dec; 20:15330338211027917.
    View in: PubMed
    Score: 0.159
  3. Ota Y, Elizagaray ML, Gupta V, Fashemi BE, Akande M, Babu P, Thuthika PK, Lomonosova E, Brill J, Sun L, Sanders B, Kuroki LM, McCourt CK, Hagemann AR, Hagemann IS, Thaker PH, Mutch DG, Powell MA, Hyrc K, Verma P, Krais J, Bitler BG, Mullen MM, Khabele D. RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer. JCI Insight. 2026 Nov 09; 11(21).
    View in: PubMed
    Score: 0.060
  4. Iwanaga R, Yamamoto TM, Gomez K, Nguyen LL, Woodruff ER, Post MD, Mikeska RG, Danis E, Danhorn T, Boorgula MP, Mitra SS, Marjon NA, Bitler BG, Brubaker LW. Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. Cancer Res Commun. 2024 08 01; 4(8):1919-1932.
    View in: PubMed
    Score: 0.051
  5. Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, Lee JM, Nair JR. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. Oncogene. 2022 11; 41(46):5020-5031.
    View in: PubMed
    Score: 0.045
  6. Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Rep. 2017 Dec 19; 21(12):3398-3405.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)